Frost lab interviewed by KENS5
- Sep 1, 2016
- 1 min read
Updated: Jul 30
The Frost lab was interviewed by San Antonio news station KENS5 to comment on the results from Biogen's phase 1b clinical trials with the drug Aducanumab, a monoclonal antibody that targets Amyloid beta aggregates.
The Frost lab was not involved in the study.
Alzforum has a nice write-up about Aducanumab: http://www.alzforum.org/therapeutics/aducanumab
Stay up to date on the progress of Aducanumab clinical trials.
Comments